Driven by strong sales across its line of drugs and services, Genzyme ( GENZ) raised guidance for fourth-quarter earnings and bettered expectations for revenue. The Cambridge, Mass., company said after the bell Tuesday that its revenue increased by 23% to $591 million, compared with the same quarter of 2003. Analysts polled by Thomson First Call were expecting sales of $582.3 million. Genzyme now expects a pro forma profit per share ranging from $1.75 to $1.80, compared with earlier guidance of $1.65 to $1.75 per share. Wall Street was expecting EPS of $1.77 a share. Revenue for the year will increase 39% to $2.2 billion, a bit better than analyst estimates of $2.19 billion. Genzyme will provide detailed financial guidance for 2005 on Feb. 17. The company initially projects 2005 revenue of $2.5 billion to $2.7 billion. It also anticipates non-GAAP earnings of $2.08 to $2.16 a share. GAAP EPS will be lower than the projected non-GAAP EPS because it will reflect amortization, one-time items and contingent convertible securities. The stock gained $2.04 a share after hours, an increase of 3.6%, to $59.10. Genzyme ended regular trading with a loss of 13 cents to $57.06.